RecruitingPhase 2NCT06831916

Impact of Cannabinoids on Menopause Symptoms

Effects of Hemp-Derived Cannabinoids on Menopause Symptoms


Sponsor

Washington State University

Enrollment

100 participants

Start Date

Mar 3, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of the study is to examine the impact of the hemp-derived minor cannabinoids on symptoms of menopause/perimenopause.


Eligibility

Sex: FEMALEMin Age: 40 YearsMax Age: 60 Years

Inclusion Criteria9

  • designated female at birth
  • years of age
  • able to give informed consent (no intellectual disability)
  • stable pharmacotherapeutic regimen, no change in the past 3 months
  • abstinent from regular cannabis use (\<1x/month) for past year, and willing to abstain from use for 3 months
  • abstinent for supplements, don't add any supplements (no changes in past 3 months)
  • own a smartphone
  • have access to Zoom on a secure, stable internet connection
  • perimenopausal or menopausal

Exclusion Criteria10

  • currently taking anti-depressant, anti-anxiety, and/or antipsychotic medication
  • severe depression, neurovegetative symptoms, or current suicidality
  • psychosis or family history of psychosis
  • pregnant or breastfeeding
  • chemotherapy
  • hypotension
  • drug testing for work or other reasons
  • illicit drug use in past 3 months (cannabis not illicit)
  • heavy alcohol use (4 drinks more than 4x/week)
  • international/air travel planned for more than one week in the next 3 months

Interventions

DIETARY_SUPPLEMENTActive Cannabinoid Product

Participants will be administered a product with minor cannabinoids and terpenes.

OTHERPlacebo

Participants will be administered a placebo.


Locations(1)

Washington State University - Pullman Campus

Pullman, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06831916


Related Trials